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Abstract 
Background 
There is a need to test the effectiveness of new educational interventions for people with 
poorly controlled epilepsy. The SMILE (self-management education for adults with poorly 
controlled epilepsy) trial evaluates a complex service intervention tha t involves a 2-day self-
management course with the aim of improving quality of life and clinical outcomes. This 
article describes the statistical, economic, and qualitative analysis plan for the trial.  
Methods and design 
SMILE is a pragmatic, parallel design, two-arm, multi-centre randomised controlled 
superiority trial of a group-based interactive course compared with treatment as usual for 
people who have experienced two or more seizures in the past 12 months.  
Results 
A summary of the objectives and design of the trial are reported as well as the manner in 
which the data will be summarised and inferentially analysed. This includes the type of 
modelling that will be employed for each of the primary and secondary outcomes and the 
methods by which the assumptions of these models will be checked. Strategies are described 
for handling clustering of outcome data, missing observations, and treatment non-
compliance. 
Conclusion 
This update to the previously published trial protocol provides a description of the trial 
analysis which is transparent and specified before any outcome data are available. It also 
provides guidance to those planning the analysis of similar trials.  
Trial registration 
Current Controlled Trials ISRCTN57937389; date assigned: 27 March 2013.  
Keywords 
Statistical analysis plan, SMILE trial, epilepsy, self-management education, randomised 
controlled trial 
Update 
Background 
Epilepsy 
Epilepsy is a long-term neurological condition, which affects approximately 1 % of the UK 
population [1]. After diagnosis, roughly 40 % of patients continue to experience at least two 
seizures per year [2] and the consequences for this group include elevated risks of injury, 
depression, and premature death [1]. From the perspective of health service provision, poorly 
controlled epilepsy is expensive (€2,000–€11,500 per case in 2004) [3]. The overwhelming 
majority of admissions for epilepsy are on an emergency basis [4], making it the sixth most 
common cause of emergency admission for chronic conditions in the UK [5] and adding 
considerably to health-care cost. 
Providing patients with the ability to manage long-term conditions and reducing emergency 
admissions are key aims of the National Health Service (NHS). For people with poorly 
controlled epilepsy, this means increasing patients’ confidence in their ability to recognise 
triggers for seizures [6] and improving their adherence to antiepileptic drugs (AEDs) [7, 8]. 
Routine NHS policy for another chronic illness, diabetes, is the offer of group education (e.g., 
diabetes education and self-management for ongoing and newly diagnosed, or DESMOND 
[9]), and there is now demand for similar courses for those with epilepsy. This is supported 
by the finding that a third of those with poorly controlled epilepsy have been told lit tle about 
the disease and the side effects of AEDs [10].  
Of a number of epilepsy interventions reviewed by the Cochrane collaboration [11, 12], only 
one has been thoroughly assessed and shown potential benefit in the UK. This group 
intervention was developed in Germany, where it was called Modular Service Package in 
Epilepsy (MOSES) [13]. A trial of this reported improved knowledge about the condition, 
enhanced control of seizures, and better acceptance of AEDs. The intervention has been 
adapted for use in the UK and is referred to here as the SMILE (self-management education 
for adults with poorly controlled epilepsy) trial.  
SMILE trial 
The SMILE trial is a parallel design, two-arm, multi-centre randomised controlled superiority 
trial of a 2-day self-management course for adults with poorly controlled epilepsy. 
Participants are randomly allocated to receive either SMILE and treatment as usual (TAU) or 
TAU alone, and randomisation is stratified by treatment centre. The aim is to test whether the 
intervention affects quality of life, clinical outcomes, and cost-effectiveness of health service 
use at 6 and 12 months after randomisation. Blinding is planned for outcome assessors and 
the trial statistician. See protocol article for further details [14].  
This article describes the statistical analysis plan for the main analyses of the trial. The plan 
was finalised and approved by the Trial Steering Committee on 3 March 2014, before any 
outcome data were available.  
Research questions 
Primary objective 
The primary objective is to examine the treatment difference in Quality of Life in Epilepsy-
31 (QOLIE-31) [15] scores between participants allocated to self-management education 
(SMILE) versus those allocated to TAU at 12 months after randomisation.  
Secondary objectives 
The secondary objectives are the following: 
1. To investigate the treatment difference in QOLIE-31 between participants allocated to 
SMILE and those allocated to TAU at 6 months after randomisation.  
2. To investigate the treatment effect on seizure frequency as recorded using the scale of 
Baker et al. [16] between participants allocated to SMILE and those allocated to TAU at 6 
and 12 months after randomisation.  
3. To investigate the treatment effect on seizure frequency as recorded using the scale of 
Thapar et al. [17] between participants allocated to SMILE and those allocated to TAU at 
6 and 12 months after randomisation.  
4. To investigate the treatment effect on time elapsed since last seizure of allocation to 
SMILE compared with those offered TAU at 6 and 12 months after randomisation. 
5. To investigate the treatment difference in self-perceived impact of epilepsy (as measured 
by the Impact of Epilepsy scale [18]) between those allocated to SMILE and those offered 
TAU at 6 and 12 months after randomisation. 
6. To investigate the treatment difference in medication management as measured by using 
the Epilepsy Self-Management Questionnaire [7] between participants allocated to 
SMILE and those allocated to TAU at 12 months after randomisation.  
7. To investigate the treatment difference in medication adverse events (AEs) as measured 
by two questions from QOLIE-31 [15] between participants allocated to SMILE and 
those allocated to TAU at 6 and 12 months after randomisation.  
8. To investigate the treatment effect on psychological distress as measured by the Hospital 
Anxiety and Depression Scale (HADS) [19] between participants allocated to SMILE and 
those allotted to TAU at 12 months after randomisation.  
9. To investigate the treatment difference in perceived stigma as measured by Jacoby’s 
Stigma of Epilepsy scale [20] between participants allocated to SMILE and those allotted 
to TAU at 12 months after randomisation.  
10. To investigate the treatment effect on self-efficacy in management of epilepsy (using the 
mastery/control of epilepsy scale [21]) between participants allocated to SMILE and 
those allocated to TAU at 12 months after randomisation.  
11. To investigate the treatment difference in cost-effectiveness of health service use between 
participants randomly assigned to SMILE and those randomly assigned to TAU at 12 
months after randomisation. 
12. To conduct an in-depth qualitative interview study to investigate SMILE users’ views on 
their participation in, and the perceived benefits of, the intervention. 
See protocol for further details of measures [14].  
Trial design 
Recruitment procedure and randomisation 
Research workers visit participants at their home or a place of their choice and explain the 
trial in detail. Those individuals who meet the eligib ility criteria are asked to provide 
informed written consent and baseline assessments. Consenting individuals who provide 
baseline data are randomly assigned to one of the treatment arms in a 1:1 ratio. See Fig. 1 for 
an illustration of the process by which patients are screened, recruited, randomly assigned, 
and followed up. Randomisation is at the patient level and is performed by using an online 
randomisation system set up by the King’s Clinical Trials Unit (KCTU) at the Institute of 
Psychiatry, Psychology and Neuroscience in London. Randomisation is stratified by 
treatment centre. A set of patients is randomly assigned with fixed block sizes of two to 
ensure that equal numbers of patients are allocated to the two arms within each treatment 
centre. The procedure is as follows: on receipt of the baseline questionnaire and after between 
14 and 24 participants have been recruited to a site, the trial coordinator electronically 
submits details of the set of participants to the KCTU. The system immediately notifies the 
trial coordinator of successful randomisation and the trial arm to which the participant has 
been allocated. A record of the allocation outcome is kept in the KCTU randomisation 
database and later linked to the main dataset.  
Fig. 1 CONSORT (Consolidated Standards of Reporting Trials) diagram. SMILE self-
management education for adults with poorly controlled epilepsy 
Ethical approval was given by the National Research Ethics Service London – Fulham 
(reference 12/LO/1962). 
Sample size 
The primary intention-to-treat (ITT) analyses will compare two equal-sized treatment arms, 
treatment or control, on the quality-of-life scale (QOLIE-31) at 12 months. Two drug trials 
that used this scale as an outcome showed standardised effect sizes of d = 0.33 [22] and 0.59 
[23]. An overall sample size of 320 participants (randomly assigned 1:1) would provide 91.3 
% power to detect an effect size of d = 0.40 on the QOLIE-31 using an analysis of covariance 
with two-sided 5 % significance tests. A value of d = 0.40 corresponds to a change of around 
6–7 points on the overall quality-of- life score. 
Since the active treatment is a group treatment delivered by different educational facilitators 
within sites, we must allow for standard error inflation due to training group effe cts. 
Assuming an average group size of 10 people with epilepsy and an intra-group correlation 
between QOLIE-31 scores of intra-class correlation coefficient (ICC) of 0.025 (a correlation 
of 0.05 would be expected for intermediate outcomes but would be lower for distal outcomes 
such as quality of life [24]), we estimated that 160 patients in the control arm and 16 groups 
of 10 patients in the SMILE arm would provide 91.3 % power to detect an effect of d = 0.40.  
The estimated attrition rate was based on data from a study of rehabilitation for people with 
severe epilepsy which had a 25 % loss at 1 year (NIHR SDO 08/1815/234). Therefore, to 
ensure adequate and equal-sized groups, a sample of 428 patients is required (n = 320/0.75; 
214 patients per arm). 
Timing and visit windows of follow-up 
Participants will complete a limited selection of follow-up measures at 6 months after 
randomisation by using a questionnaire sent to them in the post. This comprises quality of 
life, seizure frequency, time elapsed since last seizure, and impact of epilepsy. The full range 
of follow-up measures will be completed at 12 months after randomisation by face-to-face 
interview with a research assistant. The aim is for follow-up assessments to be collected 
within 3 weeks of the intended date. 
Minimising attrition 
It is expected that some participants will be lost to follow-up and this has been accounted for 
in the sample size calculation. However, every effort will be made to minimise such attrition, 
by following the recommendations of recent research [25]. A sequence of telephone 
reminders will be used to maximise the collection of follow-up data, especially at the 6-
month assessment. This assessment has been specifically condensed in order to reduce patient 
burden. An additional measure to increase adherence is the distribution of £20 vouchers 
following the 12-month assessment. 
Blinding 
Outcome assessors and the trial statistician will be blind to participants’ allocated treatment 
arm. At the start of each follow-up assessment, interview participants are requested not to 
reveal to the researcher which group they were allocated to. If a re searcher is unblinded at the 
6-month outcome visit, a different researcher will conduct the next follow-up assessment. 
Additionally, the trial databases have been designed specifically to enable data entry without 
unblinding researchers. This has been achieved by creating separate databases for recording 
outcome data, course attendance, and educational facilitator information. We are assessing 
how well researchers were kept blind by asking the assessor to make a guess as to which 
treatment each participant was allocated to at the end of follow-up. 
Reporting 
The trial results will be reported in a manner that is consistent with the recommendations of 
the updated CONSORT (Consolidated Standards of Reporting Trials) guidelines for parallel 
group trials [26]. Additionally, the report will follow the CONSORT extensions on pragmatic 
and non-pharmacologic trials [27, 28]. 
Description of data 
Baseline comparability of randomly assigned groups 
Baseline descriptions of participants’ demographic and clinical data will be reported by 
treatment group and overall. Minima and maxima, means and standard deviations, and 
medians and quartiles will be used for continuous variables as appropriate. Frequencies and 
proportions will be presented for categorical variables. No significance testing will be used to 
test baseline differences between the trial arms.  
Adherence to allocated treatment 
Adherence is defined as being in attendance at the beginning and end of each of the two days 
of the self-management course. Adherence versus non-adherence with the treatment will be 
described in terms of baseline variables. The reasons for withdrawal from treatment will be 
summarised. Treatment adherence will be described by using attendance and reasons for non-
attendance. 
Loss to follow-up and missing data 
Withdrawal from trial follow-up (attrition) will be reported by intervention group. Moreover, 
the proportions of participants who are missing values on each variable will be summarised 
by trial arm and time point. 
The baseline characteristics of those missing follow-up will be compared with those with 
complete follow-up. The relationship between baseline characteristics and missing data will 
also be investigated graphically. Factors affecting missingness will be examined by using 
logistic regression for a missingness variable. This will be done by generating a binary 
variable for missingness at 12 months after randomisation and regressing this on pre-
randomisation (baseline) variables. All outcome variables will be assessed before choosing a 
representative selection. 
The relationship between compliance and loss to follow-up will be assessed. This will be 
done by using binary variables for completion of all training sessions and for drop-out at 12 
months. The relationship between these variables will be tested by using a chi-squared test. 
The results of these analyses will inform the need to use multiple imputation (MI) in the 
formal analysis. This is because these post-randomisation variables cannot be included as 
covariates in the model without changing the meaning of the results.  
Adverse events 
AEs, adverse reactions, serious AEs, and serious adverse reactions will be summarised by 
treatment arm. 
Descriptive statistics for outcome measures 
Each of the outcome measures will be described by treatment group and time point. Means 
and standard deviations or medians and interquartile ranges will be used for continuous 
variables; box plots, histograms, and Q-Q plots will be used to assess whether the distribution 
of a variable is normal. Frequencies and proportions will be used to describe categorical 
variables. 
Inference and modelling 
Inferential analysis 
The main statistical analyses will estimate the difference in mean outcomes between patients 
randomly assigned to SMILE and TAU versus TAU alone by ITT (i.e., treatment groups 
defined by result of randomisation rather than treatment received) at the various post-
treatment observation time points. This will be done by using mixed-effects linear regression 
modelling for longitudinal data, including outcome measures at all time points and 
conditioning on the stratification variable (treatment centre) and baseline measures. Group 
difference estimates and associated confidence intervals will be reported.  
Missing post-randomisation assessments will be dealt with by fitting adequate linear mixed 
models to all the variables by using maximum likelihood (ML) methods. Such an approach 
provides valid inferences under the assumption that the missing data mechanism is ignorable 
(missing at random, or MAR) and provided that predictors of missingness are included as 
covariates in the model. 
Group difference estimates and associated 95 % confidence intervals will be reported. The 
trial statistician will remain blind until the main analyses have been completed. Some 
analyses, such as modelling training group effects, estimating complier average causal effects 
(CACEs), and summarising numbers trained by each educational facilitator, cannot be 
performed blind. Such analyses will be carried out last in order to preserve blindness for as 
long as possible. 
The significance level will be 5 % (two-sided) for the primary outcome. Secondary analyses 
will be carried out at the 5 % level but will have to be interpreted with care as multiple testing 
is not taken account of. Sensitivity analyses will be used to assess the robustness of 
conclusions to non- ignorable missing outcome data. 
Analysis of primary outcome 
The analysis population will include all randomly assigned patients. The primary outcome is 
quality of life, as measured by the QOLIE-31, at 12 months after randomisation. Quality of 
life at both post-treatment time points (6 and 12 months after randomisation) will be 
modelled simultaneously. These outcomes will constitute the dependent variable, and quality 
of life at baseline, treatment centre, baseline predictors of drop-out, trial arm, time dummy 
variables, and a treatment*time interaction term will be included as explanatory variables. 
This last term will allow the model to provide the treatment effect estimate at the primary 
time point (12 months after randomisation). The covariance matrix of the repeated measures 
will be carefully modelled: an unstructured covariance matrix and the covariance matrix 
implied by a participant-varying random intercept model will be formally compared, and the 
best covariance structure will be identified. This analysis is valid provided that missing 
values in quality-of- life outcomes are MAR. This is to say that, given the observed variables 
that have been included in the analysis model, the missingness pattern does not depend on 
any unobserved/unmodelled data.  
The relationship between baseline variables and missing outcome data will be assessed by 
using logistic regression with an outcome variable that represents whether outcome quality-
of- life data are present or missing. Should any baseline variables be predictive of 
missingness, these will be included in the model as covariates. Should the post-treatment 
variable “compliance with treatment” predict missingness, MI will be used to approximate an 
ML estimator under this form of MAR [29]. The impact of departures from MAR on 
treatment effects will be assessed by using sensitivity analysis [30].  
Potential clustering due to participants attending the same educational group (and therefore 
sharing the same interventionist) in the SMILE arm will also be assessed by exploring the 
variability between these groups. This will be summarised by using the ICC. It is expected 
that a statistical dependence will exist and that this will need to be addressed in the mode lling 
process. Therefore, it is anticipated that models will need to include random effects that vary 
with educational group in this trial arm. 
Analysis of secondary outcomes 
Secondary patient outcomes relating to the quality of life (at 6 months after randomisation), 
impact of epilepsy, medication management, psychological distress, and mastery/control of 
epilepsy will be analysed by using linear mixed models and an approach similar to that 
described above. 
Medication adverse effects and perceived stigma are unlikely to be normally distributed. 
Transformations will be investigated for these outcomes. Failing this, other types of mixed 
models, such as a mixed logistic model, will be considered.  
Seizure frequency as measured by using the scale of Thapar et a l. is a count variable and will 
be analysed by using a type of Poisson mixed model, and allowance will be made for 
overdispersion/varying exposure periods. Seizure frequency using the scale of Baker et al. is 
an ordinal variable and will be analysed by using a mixed ordinal logit model. 
Time (days) elapsed since last seizure is measured pre-randomisation (at baseline) and at 6 
and 12 months after randomisation. Such a variable will be analysed after a log 
transformation. If the data are truncated, survival modelling will be considered. 
Statistical considerations 
Stratification and clustering 
Randomisation is stratified by treatment centre (of which there are up to 15). Therefore, it is 
important to include this variable as a covariate in the modelling process. The structure of the 
majority of the data is longitudinal, and repeated measurements are taken at baseline and 6 
and 12 months after randomisation. This correlation between participants’ repeated 
observations is being taken into account by a modelling process for the covariance matrix. It 
is also possible that clustering will be seen within educational facilitators/educational groups 
within the SMILE arm. 
Missing scale items 
The number (percentage) with complete data will be reported. The ideal approach is to use 
missing value guidance provided by the developers of the scales. When such guidance is not 
available, scales will be prorated for an individual if not more than 20 % of items are missing. 
For example, in a scale with 10 items, prorating will be applied to individuals with one or two 
items missing. The average value for the eight or nine complete items will be calculated for 
that individual and used to replace the missing values. The scale score will be calculated on 
the basis of the complete values and these replacements. 
Missing baseline data 
Missing baseline data should not be a problem. However, if we encounter missing baseline 
values of outcome variables, these can be singly imputed according to White and Thompson 
[31] without incurring bias in trial arm effect estimates. 
Missing outcome data 
Where there are two outcome time points, missing post-randomisation assessments will be 
dealt with by fitting linear mixed models to all the available data by using maximum 
likelihood methods. Such an approach provides valid inferences under the assumptions that 
the missing data mechanism is ignorable (or MAR) and that pre-randomisation data are 
available for the scale. If post-treatment variables such as compliance with treatment are 
found to be predictive of drop-out, multiple imputation will be considered. This will be 
assessed through the use of a chi-squared test of independence. 
Method for handling multiple comparisons 
For the primary outcome, no formal adjustment of the P value for multiple testing is 
necessary. The analyses of the secondary outcomes will also not be adjusted for multiple 
outcome comparisons. Thus, care should be taken in the interpretation of inferences for the 
numerous secondary outcomes. (Results will need to be interpreted as hypotheses-generating 
and subject to replication.) 
Method for handling non-compliance 
In addition to the primary ITT analysis, the effect of actually receiving treatment as defined 
in the protocol (its efficacy) will be estimated for the primary outcome. If non-adherence with 
the active treatment is high, a CACE-type analysis will be considered. Specifically, 
instrumental variable (IV) methods will be used to assess the efficacy of the SMILE 
treatment. Such methods evaluate the causal effect of SMILE on a clinica l outcome in the 
subpopulation who would comply with SMILE. The application of IV methods for 
explanatory evaluation of randomised controlled trials has been advocated because random 
allocation itself provides a strong instrument for treatment receipt [32]. IV regression will be 
carried out by using the two-stage least squares estimator as implemented in the Stata 
command “ivregress 2sls”.  
Model assumption checks 
The models assume normally distributed outcomes; this will have been checked when 
describing the data, and if substantial departures from normality occur, transformations will 
be considered. Residuals will be plotted to check for normality and inspected for outliers. 
This is expected to be unnecessary for the primary outcome but will be undertaken partly in 
order to explore the data and to maintain a consistent method for all outcomes.  
Sensitivity analyses 
The impact of departures from MAR on treatment effects of continuous outcomes will be 
assessed by using sensitivity analysis. This will be done for the quality-of- life outcomes and 
will be based on the investigators’ opinion about the range of possible mean differences in 
outcome between those with missing data and those with observed values in the two trial 
arms [30]. 
Planned subgroup analyses 
The trial has not been designed (powered) to assess treatment effects within subgroups. As a 
consequence, no such subgroup analyses are described.  
Software 
Data management will employ an online data collection system for clinical trials (MACRO; 
InferMed Limited, London, UK). This is hosted on a dedicated server at King’s College 
London and managed by the KCTU. The KCTU Data Manager will extract data periodically 
as needed. Stata will be used for data description and the main inferential analysis.  
Economic analysis plan 
Heath economic objectives (secondary objective 11) 
We will take both a health service and a societal perspective in the economic evaluation. The 
costs of the intervention will be calculated by taking into account staff time needed for 
training, supervision, and delivery of the educational session and will also include overheads 
and capital costs. The cost per session will be estimated by combining the above information 
with activity data. The Client Service Receipt Inventory will be adapted and used to record 
the use of other services and also unpaid carer time and time lost from work. The service use 
data will be combined with relevant unit cost information [33]. Lost employment costs will 
be calculated by combining lost work time with average wage rates. Health-care and societal 
costs at follow-up will be compared between the two arms by using a regression model with 
baseline costs controlled for. Cost data are often skewed, and we will use bootstrapping to 
generate 95 % confidence intervals around the cost differences. To assess cost-effectiveness, 
we will combine costs with data for the primary outcome measure at 12 months. Cost utility 
will be assessed by combining costs with quality-adjusted life years (QALYs), which will be 
generated from the European Quality of Life-5 Dimensions (EQ-5D) questionnaire. If the 
intervention results in better outcomes and lower costs, it will be considered to be 
“dominant”. If it results in better outcomes and higher costs, incremental cost-effectiveness 
ratios will be calculated to show the extra cost incurred to achieve a one-unit improvement on 
the QOLIE-31 or one extra QALY (both at 12 months). Uncertainty around the estimates of 
cost-effectiveness and cost utility will be made by taking 1000 cost-outcome combinations at 
random (and with replacement) from the data by using bootstrap methods and plotted on a 
cost-effectiveness plane. Interpretation of the results will use cost-effectiveness acceptability 
curves to show the probability that the intervention is the most cost-effective option for a 
range of different values placed on an improvement in outcome. For QALYs, the range will 
be £0 to £100,000. The range for improvements on the QOLIE-31 will be chosen so that 
values at which the intervention or TAU has a 50 % and 70 % and 90 % likelihood of being 
cost-effective are identified. 
Economic measures 
Client Services Receipt Inventory: This will record contacts with health-care services at 
baseline and over the follow-up. It includes hospital admissions, contact with primary and 
community care, and receipt of care from family and friends. In addition, it includes lost 
work time. 
EQ-5D: QALYs will be calculated from the EQ-5D health state classification instrument. 
This covers five domains: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. For each domain, the respondent chooses one of five levels of 
functioning, from good to poor. The five levels for each of the five domains are used to 
define unique health states to which a pre-estimated “utility” value will be attached.  
Qualitative analysis plan (secondary objective 12) 
Aim 
Qualitative studies are increasingly conducted as a component of the evaluation of “complex” 
interventions with the aim of supplementing quantitative measures and contributing to the 
wider implementation of health-care interventions [34]. The present study aimed to 
complement the quantitative measures by providing an in-depth account of (1) participants’ 
perceptions of what they valued and any negative aspects of the intervention and (2) whether 
and in what ways participants continued to make use of the training received.  
Methods 
Study group 
Pilot interviews at 12 months post- intervention have indicated that participants were often not 
able to recall whether they had learned particular information about epilepsy and its 
management from the intervention or through other sources. This supports evidence that 
ongoing seizures do impair the laying down of memory [35]. However, reducing the period 
between intervention and interviews would have possible implications for subsequent 
outcome measurement. Therefore, we will interview the control group participants 2–6 
months after they have received the control group intervention and have completed the three 
phases of quantitative data collection. 
Recruitment 
The study will be based on around 20–24 study participants who were randomly assigned to 
the SMILE (UK) control group, and the precise sample number will depend on when 
sampling saturation has been achieved and the condition that no new issues or explanations 
are elicited by further interviews [36]. Participants will be selected purposively to achieve a 
study group that is inclusive in terms of differences in gender, age, ethnicity, severity of 
seizures, and depression score. 
Interviews 
These will take place at participants’ homes or a convenient public place if preferred. 
Interviews will be semi-structured and conducted in a conversational manner with probes, 
facilitation, and clarification of responses as required. The topics covered will include 
participants’ experiences in taking part in the courses, their perceptions of things they valued 
and found of particular benefit and any negative aspects as well as any factors that 
encouraged or hindered their participation in the courses and whether and in what ways they 
have continued to make use of the training. The content of the course workbook will also be 
discussed in relation to participants’ own needs and lifestyles.  
Analysis 
The interviews will be audio-recorded (with consent) and transcribed. The analysis will 
proceed alongside data collection and will be based on a framework approach [37]. This is 
suitable for small numbers of cases and ensures that each case is fully taken into account in 
the analysis. This analytic approach requires identifying initial themes that are then grouped 
into main and sub-themes. This is applied to the raw transcript data for each interview, and a 
thematic “chart” is created that summarises information for each theme and allows cross-case 
and within-case analysis through a process of constant comparison, and particular attention is 
paid to deviant cases. This approach to analysis can be undertaken manually or by using new 
framework matrices from NVivo9 or 10. Two members of the research team will participate 
in data analysis to reduce bias in the identification and interpretation of themes and 
categories. 
Outputs 
The findings of this nested qualitative study will contribute to outcome assessment of the trial 
by providing explanations and a greater understanding of the quantitative assessment as well 
as exploring issues not covered by these assessments. The findings may also be written up as 
a stand-alone article that examines patient-based assessments of a self-management 
intervention. 
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